Moderna Faces Key FDA Decision on mRNA Flu Vaccine Amid Pipeline Push and Financial Scrutiny
Moderna awaits an August 2026 FDA decision on its mRNA flu vaccine while expanding into oncology, autoimmune disease, and monkeypox. Its COVID-19 vaccine Spikevax remains central amid financial losses and cautious analyst sentiment.
Moderna, Inc. awaits an FDA decision on its investigational mRNA flu vaccine, expected by August 5, 2026, as the company works to diversify its pipeline beyond COVID-19. The clinical-stage biotechnology firm continues to post net losses and faces a cautious analyst consensus, with a price target of $49 well below its current trading level of $67.01.
The company's lead product, Spikevax, remains a cornerstone of U.S. COVID-19 vaccination efforts. Spikevax is an mRNA vaccine that encodes the SARS-CoV-2 spike protein using lipid nanoparticle delivery and is administered via intramuscular injection. It holds FDA approval for individuals 12 years and older, with an emergency use authorization for younger children. Moderna updates Spikevax formulations to address circulating variants, reflecting the adaptability of its mRNA platform. The vaccine is distributed through commercial channels and public health programs, with availability subject to insurance coverage and federal initiatives.
Beyond COVID-19, Moderna is expanding into oncology and autoimmune diseases, areas that have attracted analysts' attention. The company's pipeline also includes mRNA-1769, an investigational mRNA vaccine currently in clinical trials for monkeypox prevention. This candidate is part of a broader competitive landscape that includes Bavarian Nordic's marketed MVA-BN vaccine and BioNTech's BNT166a, which is in Phase I/II trials.
Moderna reported persistent net losses, though it has beaten EPS estimates in recent quarters, while revenue has declined from pandemic peaks. The company's market capitalization stands at approximately $26.76 billion, with an enterprise value of $22.85 billion. Its stock has traded between a 52-week low of $22.36 and a high of $81.80. Moderna does not pay a dividend.